Get started
Author

Štefan Laššán

Observed names: Laššán, Štefan, S Lassan, Stefan Lassan
ORCID: 0009-0006-1201-2879
Observed ORCID: 0009-0006-1201-2879
OpenAlex ID: A5000865023
Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry study
2022 · Dragana M. Jovanovic, Martina Šterclová, et al. · Respiratory Research · 54
PDF
Pharmacological approaches to pulmonary fibrosis following COVID-19
2023 · Stefan Lassan, Tomas Tesar, et al. · Frontiers in Pharmacology · 21
PDF
Factors influencing prognosis of pneumonia in elderly patients
2004 · Martin Wawruch, Silvester Krcmery, et al. · Aging Clinical and Experimental Research · 15
Does timeliness of diagnosis influence survival and treatment response in idiopathic pulmonary fibrosis? Real- world results from the EMPIRE registry
2017 · Martina Vašáková, Nesrin Mogulkoc, et al. · European Respiratory Journal · 6
Tongue Ultrasonography in the Screening of Severe Obstructive Sleep Apnea Syndrome—Promising Potential for Overloaded Sleep Centers
2024 · Milan Smiesko, Ester Jenigarova, et al. · Diseases · 5
PDF
Metatranscriptome Analysis of Nasopharyngeal Swabs across the Varying Severity of COVID-19 Disease Demonstrated Unprecedented Species Diversity
2023 · Michaela Hyblova, Dominik Hadzega, et al. · Microorganisms · 5
PDF
Analysis of spontaneous reports of suspected adverse reactions after vaccination against COVID-19 in Slovakia
2023 · Monika Lassanova, Stefan Lassan, et al. · Frontiers in Pharmacology · 3
PDF
Analysis of comorbid conditions in 1210 IPF patients from the EMPIRE registry
2017 · Dragana M. Jovanović, Nesrin Mogulkoc, et al. · European Respiratory Journal · 3
Kontrola astmy v bežnej klinickej praxi pri liečbe fixnou kombináciou ICS/LABA
2019 · Štefan Laššán, Ildikó Téglás, et al. · Klinická farmakologie a farmacie · 1
PDF
Evaluation of roflumilast in COPD patients in a real-world European setting: results from the PROFILE EU study
2017 · Claus Vogelmeier, Nikolaos Tzanakis, et al. · European Respiratory Journal · 1
Summary
2016 · Štefan Laššán, Monika Laššánová, et al. · Klinická farmakologie a farmacie · 1
PDF
Mala by sa duálna bronchodilatačná liečba stať prvou voľbou vo farmakoterapii chronickej obštrukčnej choroby pľúc
2016 · Štefan Laššán, Monika Laššánová · Klinická farmakologie a farmacie · 1
Clinical Case Study: Treatment of Interstitial Lung Lesions Following Severe Covid-19 with Pirfenidone
2023 · Štefan Laššán, Tomáš Tesař, et al. · SSRN Electronic Journal
COVID-19 and the lung: from interstitial pneumonia to pulmonary fibrosis
2022 · Štefan Laššán, Monika Laššánová · Klinická farmakologie a farmacie
PDF
Súčasný pohľad na pneumokokovú vakcináciu u dospelých: prečo nesmieme zabúdať na konjugovanú vakcínu?
2021 · Štefan Laššán, Monika Laššánová · Klinická farmakologie a farmacie
Update in asthma pharmacotherapy
2020 · Štefan Laššán, Monika Laššánová · Klinická farmakologie a farmacie
PDF
Can clinical data predict rapid decline of lung function in idiopathic pulmonary fibrosis (IPF) patients?
2017 · Veronika Müller, Nesrin Mogulkoc, et al. · European Respiratory Journal
Anti-inflammatory treatment of stable COPD - current trends and recommendations for clinical practiceExperts statement
2017 · Štefan Laššán, Marta Hájková, et al. · Klinická farmakologie a farmacie
PDF
Abstract
2016 · Monika Laššánová, Štefan Laššán, et al. · Klinická farmakologie a farmacie
PDF
Vakcinácia a prevencia pneumokokovej komunitnej pneumónie
2015 · Štefan Laššán, Monika Laššánová · Klinická farmakologie a farmacie
Diagnosis of early lung cancer in our department.
2010 · I. Majer, Joe Demian, et al.
Current opinions on the role of inhaled corticosteroids in the treatment of chronic obstructive pulmonary disease
2007 · S Lassan, J Tisonova, et al. · Bratislavské lekárske listy/Bratislava medical journal
Works count: 23
Citation count: 116
H-index: 5
I10-index: 3
Year
Topic
Type